Search Results
Jul 06, 2026, 11:19 ET A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ: GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development
More news about: American News Group
Jun 30, 2026, 09:00 ET A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ: GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications
More news about: USA News Group
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2, 2026 /PRNewswire/ -- Most clinical-stage cancer
More news about: USA News Group
May 29, 2026, 09:00 ET The $13 Million Company Teaching the Immune System to Hunt Cancer
Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking,
More news about: USA News Group
May 19, 2026, 09:00 ET Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ: GTBP), Fate Therapeutics, Inc. (NASDAQ: FATE), Nkarta, Inc. (NASDAQ: NKTX), ImmunityBio, Inc. (NASDAQ: IBRX), INmune Bio, Inc. (NASDAQ: INMB)
More news about: Equity Insider
May 18, 2026, 14:22 ET B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Key Takeaways GT Biopharma (NASDAQ: GTBP) dosed the first patient on May 14, 2026 in a Phase 1 dose-escalation basket trial of GTB-5550, its B7-H3-targeted natural killer cell engager for solid
More news about: USA News Group
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
sectors and watch these companies as they expand market reach, accelerate growth, and unlock new opportunities: GT Biopharma, Inc. (NASDAQ: GTBP), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), Fate Therapeutics, Inc. (NASDAQ: FATE), ImmunityBio, Inc. (NASDAQ: IBRX), Coherus
More news about: Market News Updates
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
specialized platforms that can scale across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ: GTBP), ImmunityBio (NASDAQ: IBRX), Erasca, Inc. (NASDAQ: ERAS), NovaBridge Biosciences (NASDQ: NBP), and Coherus Oncology (NASDAQ:
More news about: Equity Insider
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
positions companies with proprietary engines to capture multiple therapeutic opportunities simultaneously, benefiting GT Biopharma, Inc. (NASDAQ: GTBP), ADC Therapeutics SA (NYSE: ADCT), Sutro Biopharma, Inc. (NASDAQ: STRO), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), and TScan
More news about: Equity Insider
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
transformative power of immunotherapy in blood cancers[2]. These breakthroughs position companies like GT Biopharma, Inc. (NASDAQ: GTBP), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Genmab A/S (NASDAQ: GMAB), Autolus Therapeutics plc (NASDAQ: AUTL), and Lyell
More news about: USA News Group
Dec 11, 2025, 10:17 ET Platform Technologies Drive $211B Surge in Precision Cancer Treatment
valuations as the sector pivots toward modularity and rapid reuse of validated mechanisms, creating momentum for GT Biopharma, Inc. (NASDAQ: GTBP), Erasca, Inc. (NASDAQ: ERAS), Foghorn Therapeutics Inc. (NASDAQ: FHTX), OmniAb, Inc. (NASDAQ: OABI), and Recursion Pharmaceuticals,
More news about: Equity Insider
Dec 04, 2025, 12:20 ET Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ: GTBP), Geron Corporation (NASDAQ: GERN), Kura Oncology, Inc. (NASDAQ: KURA), SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), and TScan
More news about: USA News Group
Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
natural killer cell activation, T-cell engagers, personalized vaccines, and precision delivery systems positions GT Biopharma, Inc. (NASDAQ: GTBP), Evaxion A/S (NASDAQ: EVAX), RenovoRX, Inc. (NASDAQ:RNXT), EDAP TMS S.A. (NASDAQ: EDAP), and Xencor, Inc. (NASDAQ: XNCR).
More news about: Equity Insider
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
protein degraders, early detection diagnostics, immune activation platforms, and bispecific antibodies positions GT Biopharma, Inc. (NASDAQ: GTBP), Nurix Therapeutics, Inc. (NASDAQ: NRIX), GRAIL, Inc. (NASDAQ: GRAL), C4 Therapeutics, Inc. (NASDAQ: CCCC), and Pfizer, Inc.
More news about: USA News Group
Oct 15, 2025, 09:11 ET Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
companies advancing differentiated mechanisms across multiple tumor types for significant value creation, including GT Biopharma, Inc. (NASDAQ: GTBP), IDEAYA Biosciences, Inc. (NASDAQ: IDYA), Zymeworks Inc. (NASDAQ: ZYME), Novartis AG (NYSE: NVS), and Regeneron Pharmaceuticals,
More news about: USA News Group
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
breakthrough treatments[1]. These advances position GT Biopharma, Inc. (NASDAQ: GTBP), CytoMed Therapeutics Limited (NASDAQ: GDTC), Plus Therapeutics, Inc. (NASDAQ:
More news about: Equity Insider
Oct 08, 2025, 10:58 ET Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
by 2034[3], creating powerful momentum for companies pioneering next-generation approaches including GT Biopharma, Inc. (NASDAQ: GTBP), Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Anixa Biosciences, Inc. (NASDAQ: ANIX), Tempus AI, Inc. (NASDAQ: TEM), and Citius
More news about: Equity Insider
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
backdrop of scientific momentum and institutional capital deployment, clinical-stage immunotherapy developers including GT Biopharma, Inc. (NASDAQ: GTBP), Leap Therapeutics, Inc. (NASDAQ: LPTX), IO Biotech (NASDAQ: IOBT), Celcuity Inc. (NASDAQ: CELC), and MAIA Biotechnology, Inc.
More news about: USA News Group
Oct 07, 2025, 08:00 ET Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
previously undruggable targets[5]. Clinical-stage developers advancing these differentiated mechanisms include GT Biopharma, Inc. (NASDAQ: GTBP), I-Mab (NASDAQ: IMAB), enGene Holdings Inc. (NASDAQ: ENGN), Onconetix, Inc. (NASDAQ: ONCO), and Nanobiotix S.A. (NASDAQ:
More news about: Equity Insider